These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

681 related articles for article (PubMed ID: 22394547)

  • 41. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
    Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
    Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intrastriatal and intranigral grafting of hNT neurons in the 6-OHDA rat model of Parkinson's disease.
    Baker KA; Hong M; Sadi D; Mendez I
    Exp Neurol; 2000 Apr; 162(2):350-60. PubMed ID: 10739641
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model.
    Blandini F; Levandis G; Bazzini E; Nappi G; Armentero MT
    Eur J Neurosci; 2007 Jan; 25(2):397-405. PubMed ID: 17284180
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology.
    Ulusoy A; Febbraro F; Jensen PH; Kirik D; Romero-Ramos M
    Eur J Neurosci; 2010 Aug; 32(3):409-22. PubMed ID: 20704592
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vivo extracellular recording of striatal neurons in the awake rat following unilateral 6-hydroxydopamine lesions.
    Chen MT; Morales M; Woodward DJ; Hoffer BJ; Janak PH
    Exp Neurol; 2001 Sep; 171(1):72-83. PubMed ID: 11520122
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Urinary 8-OHdG elevations in a partial lesion rat model of Parkinson's disease correlate with behavioral symptoms and nigrostriatal dopaminergic depletion.
    Kikuchi Y; Yasuhara T; Agari T; Kondo A; Kuramoto S; Kameda M; Kadota T; Baba T; Tajiri N; Wang F; Tayra JT; Liang H; Miyoshi Y; Borlongan CV; Date I
    J Cell Physiol; 2011 May; 226(5):1390-8. PubMed ID: 20945350
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of 6-hydroxydopamine-induced severe or partial lesion of the nigrostriatal pathway on the neuronal activity of pallido-subthalamic network in the rat.
    Breit S; Bouali-Benazzouz R; Popa RC; Gasser T; Benabid AL; Benazzouz A
    Exp Neurol; 2007 May; 205(1):36-47. PubMed ID: 17395181
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates.
    Purisai MG; McCormack AL; Langston WJ; Johnston LC; Di Monte DA
    Neurobiol Dis; 2005 Dec; 20(3):898-906. PubMed ID: 16006134
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of acupuncture on 6-hydroxydopamine-induced nigrostratal dopaminergic neuronal cell death in rats.
    Kim YK; Lim HH; Song YK; Lee HH; Lim S; Han SM; Kim CJ
    Neurosci Lett; 2005 Aug 12-19; 384(1-2):133-8. PubMed ID: 15893426
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease.
    O'Neill MJ; Murray TK; Whalley K; Ward MA; Hicks CA; Woodhouse S; Osborne DJ; Skolnick P
    Eur J Pharmacol; 2004 Feb; 486(2):163-74. PubMed ID: 14975705
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease.
    Cunningham LA; Su C
    Exp Neurol; 2002 Apr; 174(2):230-42. PubMed ID: 11922664
    [TBL] [Abstract][Full Text] [Related]  

  • 52. α-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model.
    Sanchez-Guajardo V; Annibali A; Jensen PH; Romero-Ramos M
    J Neuropathol Exp Neurol; 2013 Jul; 72(7):624-45. PubMed ID: 23771222
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intrastriatal injection of sonic hedgehog reduces behavioral impairment in a rat model of Parkinson's disease.
    Tsuboi K; Shults CW
    Exp Neurol; 2002 Jan; 173(1):95-104. PubMed ID: 11771942
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alpha-synuclein overexpression model.
    Mochizuki H; Yamada M; Mizuno Y
    J Neural Transm Suppl; 2006; (70):281-4. PubMed ID: 17017543
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Further characterisation of the LPS model of Parkinson's disease: a comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat.
    Hoban DB; Connaughton E; Connaughton C; Hogan G; Thornton C; Mulcahy P; Moloney TC; Dowd E
    Brain Behav Immun; 2013 Jan; 27(1):91-100. PubMed ID: 23044176
    [TBL] [Abstract][Full Text] [Related]  

  • 56. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias.
    Paillé V; Henry V; Lescaudron L; Brachet P; Damier P
    Mov Disord; 2007 Mar; 22(4):533-9. PubMed ID: 17230470
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Partial dopamine loss enhances activated caspase-3 activity: differential outcomes in striatal projection systems.
    Ariano MA; Grissell AE; Littlejohn FC; Buchanan TM; Elsworth JD; Collier TJ; Steece-Collier K
    J Neurosci Res; 2005 Nov; 82(3):387-96. PubMed ID: 16180225
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
    Aponso PM; Faull RL; Connor B
    Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
    Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.